NO20063571L - Framgangsmate for framstilling av lav-krystallinsk oltipraz eller amorf oltipraz - Google Patents

Framgangsmate for framstilling av lav-krystallinsk oltipraz eller amorf oltipraz

Info

Publication number
NO20063571L
NO20063571L NO20063571A NO20063571A NO20063571L NO 20063571 L NO20063571 L NO 20063571L NO 20063571 A NO20063571 A NO 20063571A NO 20063571 A NO20063571 A NO 20063571A NO 20063571 L NO20063571 L NO 20063571L
Authority
NO
Norway
Prior art keywords
oltipraz
preparation
amorphous
crystalline
low
Prior art date
Application number
NO20063571A
Other languages
English (en)
Norwegian (no)
Inventor
Cheong Weon Cho
Kyoung Rae Kang
Sang Ho Lee
Jeong Ku
Taekrho Kim
Sung Hak Lee
Jae Mook Choi
Jun Hee Cheon
Tae Kun An
Hyun Jung Park
Eun Kyung Jeon
Kwang Do Choi
Jee Woong Lim
Kwang Hee Hong
Hyesuk Hong
Il Hwan Kim
Tae Hyoung Kim
Nak Hyun Choi
Young Hoon Kim
Kyu Jeong Yeon
Original Assignee
Krjin Hae Tak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krjin Hae Tak filed Critical Krjin Hae Tak
Publication of NO20063571L publication Critical patent/NO20063571L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D5/00—Sheets united without binding to form pads or blocks
    • B42D5/04—Calendar blocks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D15/00—Printed matter of special format or style not otherwise provided for
    • B42D15/02—Postcards; Greeting, menu, business or like cards; Letter cards or letter-sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20063571A 2004-01-27 2006-08-07 Framgangsmate for framstilling av lav-krystallinsk oltipraz eller amorf oltipraz NO20063571L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040005000A KR100629771B1 (ko) 2004-01-27 2004-01-27 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
PCT/KR2005/000232 WO2005070397A1 (en) 2004-01-27 2005-01-27 Method of preparing low-crystallinity oltipraz or amorphous oltipraz

Publications (1)

Publication Number Publication Date
NO20063571L true NO20063571L (no) 2006-10-19

Family

ID=36950958

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063571A NO20063571L (no) 2004-01-27 2006-08-07 Framgangsmate for framstilling av lav-krystallinsk oltipraz eller amorf oltipraz

Country Status (12)

Country Link
US (1) US20050163855A1 (ja)
EP (1) EP1737430A1 (ja)
JP (1) JP2007519714A (ja)
KR (1) KR100629771B1 (ja)
CN (1) CN1921837A (ja)
AU (1) AU2005206063B2 (ja)
BR (1) BRPI0507094A (ja)
CA (1) CA2554588A1 (ja)
NO (1) NO20063571L (ja)
RU (1) RU2342926C2 (ja)
WO (1) WO2005070397A1 (ja)
ZA (1) ZA200607118B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
ES2382618T3 (es) * 2008-03-25 2012-06-11 Formac Pharmaceuticals N.V. Método de preparación para dispersiones sólidas
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
US20160376259A1 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
WO2018047002A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
WO2018047013A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
JP2019531344A (ja) * 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法
KR20190089851A (ko) * 2016-09-12 2019-07-31 에스티 아이피 홀딩 아게 4-메틸-5-(피라진-2-일)-3h-1,2-디티올-3-티온의 제제, 맛-개질 제제, 및 그의 제조 및 사용 방법
WO2019171174A2 (en) * 2018-03-07 2019-09-12 St Ip Holding Ag Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1851571A (en) * 1930-01-31 1932-03-29 Franklin Dev Corp Means for retarding spinning of automobile transmission gears during gear shifting operation
ES2109377T3 (es) * 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
AU2001237768A1 (en) * 2000-03-02 2001-09-12 Sang Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
NZ521710A (en) * 2000-04-07 2004-06-25 Sang Geon Kim Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
JP2007519714A (ja) 2007-07-19
EP1737430A1 (en) 2007-01-03
CN1921837A (zh) 2007-02-28
US20050163855A1 (en) 2005-07-28
KR20050077381A (ko) 2005-08-02
RU2006130733A (ru) 2008-03-10
ZA200607118B (en) 2008-04-30
KR100629771B1 (ko) 2006-09-28
AU2005206063B2 (en) 2008-10-02
AU2005206063A2 (en) 2005-08-04
CA2554588A1 (en) 2005-08-04
AU2005206063A1 (en) 2005-08-04
WO2005070397A1 (en) 2005-08-04
BRPI0507094A (pt) 2007-06-19
RU2342926C2 (ru) 2009-01-10

Similar Documents

Publication Publication Date Title
NO20063571L (no) Framgangsmate for framstilling av lav-krystallinsk oltipraz eller amorf oltipraz
MX2007004973A (es) Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
DK1017367T3 (da) Fremgangsmåder til fremstilling af polymerbaserede frigivelsespræparater
NO20064094L (no) Partikler
HK1094215A1 (en) Process for the preparation of stable polycarbodiimide dispersions in water, which are free of organic solvents and may be used as crosslinking agent
DE60107872D1 (de) Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
DE69906269T2 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
EP1847260A3 (en) Solid dispersion preparation
EP1847257A3 (en) Solid preparation comprising enteric solid dispersion
WO2008090905A1 (ja) 保存安定性に優れたｓ－アデノシル－ｌ－メチオニン含有乾燥酵母の製造方法、その製造物及びその成型された組成物
WO2005017098A3 (en) AMPHIPATHIC AND POLYCATIONIC COMPOUNDS FOR DELIVERING siRNA
JP2005509052A5 (ja)
WO2009002779A3 (en) Method of purifying a polymer
DK1689795T3 (da) Fremgangsmåde til fremstilling af polyakrolein
EA201001537A1 (ru) Гранулированная агрохимическая композиция и способы её получения
WO2009134091A3 (ko) 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자 제조방법
EP1762585A4 (en) PROCESS FOR PREPARING AN AQUEOUS DISPERSION OF AN ETHYLENE / VINYL ALCOHOL BASED COPOLYMER
NO20044926L (no) Kopolymer, fremgangsmate for fremstilling og anvendelse som film ved belegging av farmasoytiske formuleringer.
CN105504171A (zh) 一种聚丙烯接枝物及其制备方法
AU2003233064A1 (en) Process for the preparation of the amorphous form of atorvastatin calcium salt
WO2007061849A3 (en) Method of generating amorphous solid for water-insoluble pharmaceuticals
BRPI0413768A (pt) processo para preparar gránulos sólidos e gránulo de fosforoamidotioato quimicamente estável
CN102675503A (zh) 一种可光交联的聚乙烯醇衍生物的制备方法
DK0767829T3 (da) Fremstilling af flerenzymgranulater samt deres anvendelse
EP2145962A3 (en) Process for the manufacture of eptifibatide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application